Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis

Company Overview

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies that modulate key regulators of cell survival and protein homeostasis. The company’s approach centers on targeting apoptosis and protein degradation pathways to address a range of cancers and fibrotic diseases. Ascentage leverages proprietary medicinal chemistry expertise to design compounds that selectively inhibit anti-apoptotic Bcl-2 family proteins and restore normal cell death processes in tumors.

The company’s leading clinical programs include APG-1252, a dual Bcl-2/Bcl-xL inhibitor being evaluated in hematologic malignancies and solid tumors, and APG-2575, a Bcl-2 selective inhibitor with the potential for combination therapy in leukemia. In addition to its apoptosis platform, Ascentage is advancing small molecules that act on protein homeostasis targets such as the heat shock protein 90 (Hsp90) network, aiming to disrupt cancer cell growth by inducing proteotoxic stress.

Founded in Shanghai in 2013, Ascentage has built a global research and development footprint with facilities in Greater China, as well as operations in the United States and Europe. Its headquarters in Shanghai houses integrated discovery and early development laboratories, while international satellite offices support clinical operations and strategic partnerships. The company’s management team brings together industry veterans with expertise in medicinal chemistry, clinical development, and regulatory affairs.

Ascentage Pharma is publicly traded on the Hong Kong Stock Exchange and maintains an over-the-counter listing in the United States under the ticker ASPHF. Since its inception, the company has collaborated with academic institutions and biopharmaceutical partners to advance its pipeline and explore combination regimens. Ascentage continues to focus on accelerating late-stage trials and pursuing regulatory approvals across multiple markets to address unmet medical needs in oncology and beyond.

Key Stats

• Today's Range: $10.65 to $10.65
• 50-Day Range: $5.83 to $10.65
• 52-Week Range: $5.42 to $10.65
• Volume: N/A
• Average Volume: 500 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASPHF Stock Analysis - Frequently Asked Questions

How have ASPHF shares performed this year?

Ascentage Pharma Group International's stock was trading at $6.45 at the start of the year. Since then, ASPHF stock has increased by 65.1% and is now trading at $10.65.

How do I buy shares of Ascentage Pharma Group International?

Shares of ASPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ASPHF
• CIK: N/A
• Web: www.ascentagepharma.com
• Phone: 86-512-8555-7777
• Fax: N/A
• Employees: 565
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A